online medical consultations glp-1 therapy providers Indigo ⚠️ Thinking about compounded GLP-1

The delivery system to reach millions of patients already exists

Clinical trials have shown that gastrointestinal side effects are among the most common, with nausea reported in 15-20% of patients taking semaglutide for diabetes and up to 44% of those on higher doses for weight management

Advancing basal insulin replacement in type 2 diabetes inadequately controlled with insulin glargine plus oral agents: a comparison of adding albiglutide, a weekly GLP-1 receptor agonist, versus thrice-daily prandial insulin lispro

Our resident MD shares important factors to consider when using these medications

doi: 10.1155/2018/6434910

Beyond-use-date (BUD) vs